Obesity | CHOP Research Institute


The purpose of this study is to find out if an investigational drug called setmelanotide (RM-493) can help control body weight in people with certain genetic modifications in their genes that play a key role in the regulation of body weight.

The purposes of this study is to examine efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloric restriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD ≥0.01%.

The Center for Human Phenomic Science Bionutrition Unit provides a broad range of nutrition-related research services to investigators including dietary analysis and evaluation of patient intake, food frequency questionnaires, nutrition education, and calculation of study meals.

Published on
Jun 2, 2022
CHOP and Penn researchers discussed the latest findings about the mechanisms of immunity at the CHOP Research Institute 2022 Scientific Symposium.

The Center for Spatial and Functional Genomics is focused on uncovering the correct functional context of variants identified by genome-wide association studies in order to translate these discoveries into meaningful benefits for pediatric care.

Uncovering the correct functional context of genetic variants to translate genome-wide association studies into meaningful benefits for pediatric care.

Published on
Jul 9, 2021
This week’s news roundup features new findings in youth suicide risk, CAR T-cell therapy, obesity rates during the pandemic, and more.

The purpose of this research study is to find out if intranasal oxytocin (the hormone oxytocin, delivered through a nasal spray solution) will help with easy weight gain in children, adolescents, and adults with brain tumors and hypothalamic obesity syndrome.

The Shah Lab investigates obesity and its related complications. Current work includes clinical and translational studies exploring the pathophysiology and modulation of obesity-related adipose tissue and systemic inflammation using human cell lines and clinical trials.

The Roizen Lab aims to understand non-calciometabolic vitamin D effects and to use this understanding to design new therapies for common diseases like sarcopenia and obesity.